a-Synuclein is a small protein enriched in presynaptic nerve terminals throughout the brain. Though predominantly cytosolic, the protein also has a high affinity for phospholipid membranes. This membrane- binding ability is most likely essential for the protein's normal function, which consists of modulating the release of synaptic vesicles. Neuropathological and genetic data suggest that aggregated (oligomeric) species of a-synuclein are associated with neurodegeneration in Parkinson's disease (PD). The long-term objectives of the proposed research are to identify aggregated forms of a-synuclein that are valid drug targets in PD and to characterize the molecular interactions that lead to the formation of these aggregates in diseased neurons. The work described in this application is focused on the problem of whether phospholipid membranes play a role in the formation of neurotoxic a-synuclein aggregates. It is hypothesized that membranes act as a 'platform' to trigger the formation of harmful a-synuclein oligomers. The project will address this hypothesis with the following specific aims: (1) to determine whether membrane binding promotes the formation of (3-sheet-rich a-synuclein aggregates in test-tube models; (2) to determine whether a-synuclein forms membrane-bound, potentially toxic aggregates in eukaryotic cells; (3) to examine the effects of a-synuclein oxidation on the formation of membrane-bound aggregates. The aggregation of the protein on supported lipid bilayers will be monitored by total internal reflection fluorescence microscopy and attenuated total reflection Fourier transform infrared spectroscopy. The formation of a-synuclein oligomers on membranes will also be monitored in test-tube models, yeast, or dopamine neurons via (i) differential centrifugation combined with Western blot analysis; (ii) fluorescence measurements, using an environment- sensitive fluorophore; and (iii) fluorescence lifetime imaging microscopy. Cell viability studies will be conducted to determine whether the formation of membrane-bound aggregates correlates with the induction of toxicity in dopamine neurons. These methods will also be used to determine whether the oxidation of a- synuclein affects the formation of membrane-bound a-synuclein oligomers in test-tube models or eukaryotic cells. The results of these studies will provide clues as to whether the aggregation of a-synuclein on membrane surfaces is linked to neurotoxicity in PD. Evidence that membrane-bound a-synuclein oligomers are valid drug targets would facilitate the development of screening assays to identify novel therapeutics. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS049221-01A2
Application #
7028831
Study Section
Neurodegeneration and Biology of Glia Study Section (NDBG)
Program Officer
Murphy, Diane
Project Start
2006-03-01
Project End
2010-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
1
Fiscal Year
2006
Total Cost
$230,255
Indirect Cost
Name
Purdue University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Ambaw, Abeje; Zheng, Lingxing; Tambe, Mitali A et al. (2018) Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease. Mol Cell Neurosci 88:70-82
Anandhan, Annadurai; Rodriguez-Rocha, Humberto; Bohovych, Iryna et al. (2015) Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiol Dis 81:76-92
Zhang, Hangyu; Rochet, Jean-Christophe; Stanciu, Lia A (2015) Cu(II) promotes amyloid pore formation. Biochem Biophys Res Commun 464:342-7
Ysselstein, Daniel; Joshi, Mehul; Mishra, Vartika et al. (2015) Effects of impaired membrane interactions on ?-synuclein aggregation and neurotoxicity. Neurobiol Dis 79:150-63
Zhang, Hangyu; Griggs, Amy; Rochet, Jean-Christophe et al. (2013) In vitro study of ?-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway. Biophys J 104:2706-13
Pandey, Anjan P; Haque, Farzin; Rochet, Jean-Christophe et al. (2011) ?-Synuclein-induced tubule formation in lipid bilayers. J Phys Chem B 115:5886-93
Haque, Farzin; Pandey, Anjan P; Cambrea, Lee R et al. (2010) Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies. J Phys Chem B 114:4070-81
Zheng, Bin; Liao, Zhixiang; Locascio, Joseph J et al. (2010) PGC-1ýý, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2:52ra73
Su, Linhui Julie; Auluck, Pavan K; Outeiro, Tiago Fleming et al. (2010) Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 3:194-208
Lamberson, Emily R; Cambrea, Lee R; Rochet, Jean-Christophe et al. (2009) Path dependence of three-phase or two-phase end points in fluid binary lipid mixtures. J Phys Chem B 113:3431-6

Showing the most recent 10 out of 20 publications